Based on these results, selpercatinib has been approved by the FDA and EMA for adult and pediatric patients (≥ 12 years) with advanced or metastatic RET-mutant MTC who had previously been treated with cabozantinib, vandetanib or both. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.